6 completed. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
Follow Wasting Syndrome: new trials by email Literature Review of Wasting Syndrome trials Research Report on Wasting Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas BYM338 active drug, Placebo - Cachexia | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2011-08-01 | 2016-03-02 |
| Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL - HIV Infections, Cachexia | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 63 | 2004-12-01 | 2017-10-05 |
| A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss Optimune oral nutritional supplement - HIV Infections, HIV Wasting Syndrome | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 1999-05-01 | 2013-07-29 |
| AIDS Wasting in Women: Anabolic Effects of Testosterone Testosterone - AIDS Wasting Syndrome | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1998-09-01 | 2010-02-15 | |
| A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss Testosterone enanthate, Megestrol acetate - HIV Infections, HIV Wasting Syndrome | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2021-11-01 | |
| A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome Thalidomide - HIV Infections, HIV Wasting Syndrome | Phase 2 | Completed | Celgene Corporation | 75 | 2005-06-24 |
HIV Wasting Syndrome (5) · HIV Infections (4) · Acquired Immunodeficiency Syndrome (3) · Cachexia (3) · Emaciation (2) · Weight Loss (2) · AIDS-Related Complex (1) · Adenocarcinoma (1) · Anorexia (1) · Body Weight Changes (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1)
Metabolic Diseases (6) · Nutrition Disorders (6) · Nutritional and Metabolic Diseases (6) · Blood-Borne Infections (5) · Communicable Diseases (5) · Genital Diseases (5) · Immune System Diseases (5) · Immunologic Deficiency Syndromes (5) · Infections (5) · Lentivirus Infections (5) · RNA Virus Infections (5) · Retroviridae Infections (5) · Sexually Transmitted Diseases (5) · Sexually Transmitted Diseases, Viral (5) · Urogenital Diseases (5)
Megestrol Acetate (2) · Testosterone (1) · Thalidomide (1) · testosterone enanthate (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Celgene Corporation (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Novartis Pharmaceuticals (1)
United States (6) · India (1) · Lithuania (1) · Puerto Rico (1) · Romania (1) · South Africa (1) · Switzerland (1) · United Kingdom (1)
Bruce R. Bistrian, MD (1) · Fred R. Sattler, MD (1) · Jan Fourie, MD (1) · Kathleen Mulligan, MD (1) · Mulligan K (1) · Schambelan M (1) · Steven Grinspoon, MD (1) · Von Roenn JH (1)